The Story Behind DuPont’s Unprecedented Excipient Warning Letter And Tips On How To Avoid Another
Executive Summary
Insights from the FDA’s Francis Godwin on how the agency came to issue a warning letter to a DuPont excipient plant and how the normally under-the-radar sector can ensure GMP compliance.